Clinical Trial Update: Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults [Phase 1]

View source ↗

Summary

Phase 1 safety, toleration, and pharmacokinetics study of single intravenous doses of Peptide YY in overweight adults; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Peptide YY (peptide YY)

Snippet

Sponsor: Pfizer | Conditions: Obesity | Phase 1 | Status: COMPLETED